பாஸிடிவ் பின்தொடரவும் மேலே தகவல்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TMCnet News
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
[December 11, 2020]
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment –
– Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 -   
– Data to be Presented Today at the San Antonio Breast Cancer Symposium -
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, announced today final data with up to 6 months follow-up ....

United States , San Antonio , Adam Holdsworth , Annee Oshea , Elizabetha Mittendorf , Angelosm Stergiou , Life Sciences Group Inc , Oncology Program Dana Farber Brigham , National Cancer Institute , Women Cancer Center , Memorial Sloan Kettering Cancer Center , Positive Follow Up Data , Randomized Phase , Ductal Carcinoma In Situ , Immune Stimulation Augmented , Statistically Significant Difference , Immune Response , Presented Today , San Antonio Breast Cancer Symposium , Sciences Group , Chief Executive Officer , Karen Hale Distinguished Chair , Surgical Oncology , Breast Surgical Oncology Brigham , Breast Immuno Oncology Program , Cancer Center ,